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Abstract
Background: Many HIV-infected patients only access health care once they have developed advanced
symptomatic disease resulting from AIDS Defining Conditions (ADCs). We carried out a study to establish
the effect of ADCs on immunological recovery among patients initiated on antiretroviral therapy (ART).
Methods: A retrospective cohort of 427 HIV-1 patients who were initiated on ART between January
2002 and December 2006 was studied. Data on ADCs was retrieved from Joint Clinical Research Centre
(JCRC) data base and backed up by chart reviews. We employed Kaplan-Meier survival curves to estimate
median time to 50 CD4 cells/μl from the baseline value to indicate a good immunological recovery
process. Cox proportional hazard models were used at multivariate analysis.
Results: The median time to gaining 50 CD4 cells/μl from the baseline value after ART initiation was
longer in the ADC (9.3 months) compared to the non-ADC group (6.9 months) (log rank test, p = 0.027).
At multivariate analysis after adjusting for age, sex, baseline CD4 count, baseline HIV viral load, total
lymphocyte count and adherence level, factors that shortened the median time to immunological recovery
after ART initiation were belonging to the non-ADC group (HR = 1.31; 95% CI: 1.03–1.28, p = 0.028),
adherence to ART of ≥ 95% (HR = 2.22; 95% CI: 1.57–3.15, p = 0.001) and a total lymphocyte count ≥
1200 cells/mm3 (HR = 1.84; 95% CI: 1.22–2.78, p = 0.003). A low baseline CD4 count of ≤ 200 cells/μl (HR
= 0.52; 95% CI: 0.37–0.77, p = 0.001) was associated with a longer time to immunological recovery. There
was no interaction between low CD4 counts and ADC group.
Conclusion: Patients with ADCs take longer to regain their CD4 counts due to the defect in the immune
system. This may prolong their risk of morbidity and mortality.
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Introduction
During 2005, the World Health Organization (WHO) had
estimated that there were over 1.3 million people receiv-
ing anti retroviral therapy (ART) in low and middle-
income countries, representing 20% of 6.5 million esti-
mated to need it [1]. In Uganda, the estimated number of
patients on ART is over 135,000 out of 300,000 patients
in dire need of treatment and for the past 6 years its use
has markedly expanded as part of the ART scale-up that
started in 2003 with 30,000 patients[2,3].
As the number of individuals able to access treatment is
increasing, one of the challenges facing ART services in
sub-Saharan Africa is that many HIV-infected patients
only access healthcare once they have developed
advanced symptomatic disease resulting from AIDS
Defining Conditions (ADCs)[4]. The median CD4 cell
count among those enrolling in ART programmes is often
very low, which increases morbidity and mortality [4,5].
Advanced pre-treatment immunodeficiency has also been
found to be associated with diminished capacity for resto-
ration of CD4 cell counts and CD4 cell functional
responses after ART initiation. Therefore, this raises the
concern that many ADCs patients entering ART pro-
grammes in sub-Saharan Africa may have limited poten-
tial for immunological recovery[5,6]. This problem is
further compounded by the fact that the number of stud-
ies on people with ADCs and immunological recovery are
being limited. In this paper we examine the effect of ADCs
on immunologic recovery among naive patients initiated
on ART at Joint Clinical Research Centre (JCRC), Kam-
pala, Uganda.
Methods
Study design and patient selection
This study was a retrospective cohort. JCRC is one of the
established centers providing ART and is located in Kam-
pala, the capital city of Uganda. It was founded in 1991
and has been providing anti-retroviral therapy since1996.
Combination ART (cART) became available in 1998 but
was quite expensive at that time. Generic Fixed Drug cART
which was much cheaper(about $50/month) and more
accessible by 2002 under the UNAIDS/Ministry of Health
(Uganda) HIV Drug Access Initiative Programme [7]. We
retrieved data from JCRC data base of all patients who had
been initiated on ART between 2002 and 2006. This was
backed up by chart review for all charts queried from the
data base. During the period the study was done, the data
beyond December 2006 was not yet available in the JCRC
data set. The patients were ≥ 18 years and ART naive. The
exposure of interest was the presence of ADCs at ART ini-
tiation among these patients. We classified ADCs accord-
ing to the WHO clinical staging system [8]. A patient was
classified as belonging to the ADC group if was diagnosed
with an ADC in the period 12 weeks before or 12 weeks
after ART initiation. This classification excludes patients
with tuberculosis infections who were on intensive phase
of anti-tuberculosis treatment due to the drug interactions
and poor virological response [9]. We also excluded
patients seen at baseline that had no subsequent follow-
up and patients who had previous exposure to dual ART
due to poor virological response [10]. The study was
approved by the Makerere University College of Health
Sciences Research and Ethics Committee. The primary end
point was time from ART initiation to immunological
recovery, which was defined as the attainment of ≥ 50
CD4 counts/μl above the baseline CD4 cell count that
indicated a good immunological recovery process [11,12].
Diagnostic methods
Diagnosis was done and documented in the charts by the
attending physician. This depended on history from the
patient, clinical examination, and backed up by labora-
tory results. HIV wasting syndrome was defined as more
than 10% documented loss of body weight and either
unexplained chronic diarrhea (> one month), or chronic
weakness and unexplained prolonged fever (> one
month) with pyrexia recorded on at least on one occasion
[8]. Cryptosporidiosis was diagnosed by modified Ziehl
Nielsen stain on faecal smear; cryptococcal infection was
diagnosed on Indian ink stain of cerebral spinal fluid;
muco-cutaneous herpes simplex infection and oesopha-
geal candidiasis were diagnosed clinically; tuberculosis
infections were diagnosed by presence of acid fast bacilli
from lymph node biopsy, or a pleural effusion with a lym-
phocytosis which responded to anti-tuberculosis treat-
ment. Kaposi sarcoma was diagnosed histologically,
although some cases were diagnosed clinically. Cerebral
Toxoplasmosis depended on a positive computer tomog-
raphy scan, and or a focal neurological disease with a high
titre of Ig G antibodies.
Laboratory assessment
Laboratory measurements included a complete blood cell
count, CD4 lymphocyte count, and quantitative measure-
ment of HIV load. Quality control assurance was done in
reference to international accredited laboratories; UK
National External Quality Assessment Service
(UKNEQAS) and College of American Pathologists
(CAP).
Viral load count was done with use of Amplicor monitor
standard assay, version 1.5 (Roche Molecular Systems),
with a minimum detection limit of 400 copies/ml. In
2006, an assay with a detection limit of 50 copies/ml was
acquired by the unit. Viral load count was not consistently
done.
CD4 lymphocytes were analyzed by flow cytometry (Ben-
dict Dickson, USA). This was periodically done every 6AIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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months during the routine visit to the out-patient clinic.
Frequently, this schedule was not routinely followed and
depended upon the discretion of the attending physician
during the interim visits when patients were sick. The time
to immunological recovery was estimated to the nearest
clinic visit and CD4 count. We right censored patients if
they were lost to follow-up after a period exceeding 12
weeks or when failed to gain 50 CD4 cells/μl above the
baseline value. A patient was considered lost to follow-up
if did not make contact with JCRC out-patient clinic for a
period exceeding 90 days during the study period. Adher-
ence to ART was determined according to the patient's
previous four days recall when visited the JCRC out-
patient clinic and was considered when the patient took ≥
95% of the prescribed medications [13].
Statistical analysis
We aimed to achieve a sample size with a power of 90%
to detect the differences between ADC and non-ADC
group, and was estimated using formula for survival anal-
ysis [14]. We set the level of statistical significance, α at
0.05. The data was queried in MS ACCESS, exported to MS
EXCEL and analyzed using STATA (version 8). Kaplan-
Meier survival curves were used to estimate median time
to immunological recovery. Cox regression hazard mod-
els were used to determine factors influencing time to
immunological recovery. We fitted a Cox regression mod-
els that included all variables which were statistically sig-
nificant at bivariate analysis. Sex was included in the
models because of the previous findings from a study
[15]. The interaction between baseline CD4 count and
other variables (group status, age, sex, total lymphocyte
count, adherence level and viral load) was assessed by per-
forming a Chunk test. At baseline CD4 count of 50, 100,
150, 200, 250 and 350 cells/μl, we compared the -log like-
lihood of the model with interaction terms to a model
without the interaction terms. Interaction was considered
when the difference (multiplied by 2) of the -log likeli-
hood was greater than the critical chi-square value of
12.59 at 6 degrees of freedom.
Results
We queried 609 patients from data base who were initi-
ated on antiretroviral therapy between January 1st 2002
and December 31st 2006, at JCRC out-patient clinic. This
number excludes patients who are currently enrolled in
ongoing clinical trials and patients who were monitored
by physicians outside the JCRC facility but receiving ART
at JCRC pharmacy, whose data is stored else where. A total
of 182 records were excluded because the patients were
seen once at ART initiation and lacked follow-up visits or
had previous exposure to dual ART. The remaining 427
patients whose records were used for analysis, had base-
line CD4 load count and had been seen on one or more
subsequent visits within a period of 12 months follow-up
(Figure 1). Out of 413 patients who had a baseline viral
load assay, 213 (51.2%) had a second or subsequent viral
assay. Sixty nine percent (148/213) achieved a detection
limit of 400 or less copies/ml during the first year of ART.
Among the patients that achieved viral suppression to a
detection limit of 400 or less copies/ml, 68.2% (101/148)
belonged to the non-ADC group.
Descriptive analysis
Of 427 patients who were initiated on ART, 32.3%
belonged to the ADC group. The most prevalent ADCs
were tuberculosis infections, HIV wasting syndrome,
Kaposi sarcoma, pneumocystis jerovici pneumonia and cer-
ebral toxoplasmosis (Table 1). The baseline characteristics
of 427 patients initiated on ART were comparable in the
ADC and non-ADC groups (patients who did not have
ADCs at ART initiation), with exception of CD4 counts,
adherence level, WHO stage and weight (Table 2). During
the follow-up, the mean number of consultations by the
patients (due to any infectious cause) at the out-patient
clinic in the ADC group was higher than that of the non-
ADC group, 16 (SD = 8.5) vs 7 (SD = 4.8), p = 0.020.
Bivariate analysis of socio-demographic and clinical 
factors
We studied 427 patients who contributed a total of
123,094 patient-days of follow-up. Three hundred and
twenty (74.9%) patients attained immunological recovery
during the study period, giving an overall immunological
recovery rate of 2.5 per 1000 patient-days. The propor-
tions of patients achieving immunological recovery were
13.0% (18/138), 39.9% (55/138), 56.5% (78/138),
71.7% (99/138) in the ADC group at 3, 6, 9 and 12
months respectively. For the non-ADC group, the propor-
tion of patients achieving immunological recovery were
13.1% (38/289), 40.8% (118/289), 64.0% (185/289),
77.2% (223/289) at 3, 6, 9 and 12 months respectively.
The median time to immunological recovery in the ADC
group was longer than that of the non-ADC group (271 vs
208 days), (logrank test, p = 0.019) (Figure 2).
Old age (> 40 years), having no ADC at ART initiation, a
baseline total lymphocyte count of ≥ 1200 cells/mm3 and
adherence to ART (≥ 95%) were associated with reduced
time to attain immunological recovery. A low baseline
CD4 count (≤ 200 cells/μl) and a high viral load count (≥
6.0 log copies/ml) were associated with a longer time to
attain immunological recovery (Table 3).
Multivariate analysis
The time to attain immunological recovery decreased
among patients with no ADCs, a total lymphocyte count
of ≥ 1200 cells/mm3 and those with adherence to ART was
equal or greater than 95%. A low baseline CD4 count of ≤
200 cells/μl at ART initiation was associated with a longerAIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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time to immunological recovery (Table 4). There was no
interaction between the baseline CD4 counts and other
variables (group status, age, sex, baseline viral load, base-
line total lymphocytes) at 50, 100, 150, 200, 250 and 350
cells/μl.
Discussion
In our study we found that the median time to immuno-
logical recovery after ART initiation was 271 days (9.3
months) in the ADC group compared to 208 days (6.9
months) in the non-ADC group. The ADC group status
was associated with a longer median time to immunolog-
ical recovery after ART initiation in comparison to the
non-ADC group. Factors that were independently associ-
ated with time to immunological recovery were group sta-
tus (presence or absence of ADC), baseline CD4 count,
baseline total lymphocyte count and adherence to ART.
Although, immunological responses to ART have been
estimated to be at least an increase of 50–100 CD4 cells/
μl/year after ART initiation, the median time to attain this
CD4 cell threshold has not been documented [12,16]. We
took the worst case scenario and estimated a gain of at
least 50 CD4 cells/μl/year from the baseline value to indi-
cate good immunological recovery process.
The differences in median times to immunological recov-
ery between the ADC and non-ADC group found in our
study may be a result of profound pre-treatment immuno-
suppression which is a common feature of ADCs. The
ADCs cause a loss of CD4 memory cells that represent a
component of the T-cell repertoire that is specific to most
ADC infections. The defect in the CD4 memory cells as a
result of ADCs accounts for the inability of patients with
ADCs to respond to recall antigens and evoke immuno-
logical responses leading to a slower immunological
recovery process compared to patients without ADCs [17].
Another explanation could be that the presence of ADCs
causes immune activation that leads to increased infection
of CD4 cells by HIV virus. This leads into CD4 cell
destruction and increased viral replication [18]. Our find-
ings seem to support these findings and are similar to
other studies in a multi-centre clinical trial where patients
with ADCs who were followed-up for 144 weeks who had
a slower immunological recovery than patients without
ADCs [19]. The contrasting feature of this study from our
study is that it did not determine the median time to
immunological recovery. We found that the hazard of
attaining immunological recovery when a patient had no
ADC increased by 1.3 times compared to when a patient
had an ADC.
Other determinants that favored a good immunological
recovery process after ART initiation were a baseline CD4
count (> 200 cells/μl), baseline total lymphocytes count
(≥ 1200 cells/mm3) and adherence to ART (≥ 95%). The
hazard of attaining immunological recovery reduced
when comparing a patient with ≤ 200 CD4 cells/μl to a
patient with > 200 cells/μl by 50%. Our results are consist-
ent with other studies where immunological recovery is
largely dependent on baseline CD4 count and thus the
timing of ART initiation is important in order to maximize
the CD4+ T-cell response to therapy [19]. In contrast, one
study from South African community cohort that fol-
lowed-up patients for 44 weeks, found that patients who
had a baseline CD4 count below or equal to 50 cells/μl
had equivalent or greater immunological recovery com-
pared to patients with higher baseline CD4 count [16].
We found out that there was no interaction between CD4
count and other variables (group status, viral load count,
total lymphocyte count, age, sex), although it has been
documented else where [20,21]. The lack of interaction
may be a result of inadequate power due to limited sam-
ple size among the various CD4 count strata.
Study profile of 609 patients initiating ART at JCRC Kampala,  during 2002–2006 Figure 1
Study profile of 609 patients initiating ART at JCRC 
Kampala, during 2002–2006.
182 records excluded
x 175 were patients seen only at 
baseline
x 7 patients had previous 
exposure to dual ART
Number of records 
screened, N = 609 
ADC group 
N = 138 
Non-ADC group 
N= 289 
Table 1: ADC diagnoses among 138 patients initiated on ART at 
JCRC during 2002–2006
ADC Diagnoses
N = 196
Frequency Percentage
Tuberculosis infections 63 32.1
HIV wasting syndrome 51 26.0
Kaposi sarcoma 21 10.7
Pnuemocystis jerovici pneumonia 17 8.7
Toxoplasmosis 15 7.7
Cryptococcal meningitis 12 6.1
Esophageal candidiasis 10 5.1
* Others 7 3.6
* 2 CMV retinitis, 2 HSV mucocutaneous infection > 1 month, 1 
lymphoma, 1 cryptosporidial diarrhea, 1 MAC infectionAIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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We found a significant association between adherence
level and time to immunological recovery. The hazard of
attaining immunological recovery when a patient had
adherence level of ≥ 95% compared to one of lower adher-
ence level was 2.2. The adherence level to ART in the ADC
group was much lower than the non-ADC group. Simi-
larly, the proportion of patients who achieved virological
suppression in the ADC group was lower than the non-
ADC group. The non-adherence in the ADC group could
have resulted from the pill burden as a result of the con-
comitant medications other than the drug-drug interac-
tions from the rifampicin-based and ART regimens which
has been reported else where [9]. During the intensive
phase of the anti-tuberculosis treatment, patients were
Table 2: Baseline comparison of socio-demographic and clinical characteristics of 427 patients initiated on ART at JCRC, during 2002–
2006
Variables ADC group
N = 138
Non-ADC group
N = 289
p-value
Sex (%)
Male 59(42.8) 103(35.3) 0.137
Female 79(57.2) 187(64.7)
Age (years)
Mean (SD) 40(11) 40(10) 0.331
Occupation (%)*
Salaried 36(27.1) 105(37.5) 0.185
Non-salaried 55(41.4) 106(37.9)
Peasant 6(4.5) 11(3.9)
Unemployed 36(27.1) 58(20.7)
Education (%)*
None 24(17.8) 54(19.1) 0.380
Primary 51(37.8) 88(30.9)
Post-Primary 60(44.4) 142(50.0)
Residence by district (%)*
Inside Kampala 78(58.7) 136(51.5) 0.178
Outside Kampala 55(41.4) 128(48.5)
Marital status (%)*
Married 57(42.5) 105(38.8) 0.818
Single 40(29.9) 88(32.5)
Widowed 23(17.2) 53(19.6)
Separated/divorced 14(10.5) 25(9.1)
CD4 (cells/μl)
Median (IQR) 74(28, 75) 147(64, 240) 0.001
Viral load (copies log10/ml)
Median (IQR) 6.8(6.0, 12.1) 6.0(6.0, 11.6) 0.256
TLC† (cells/mm3) × 103
Median (IQR) 1.8(1.3, 2.6) 1.9(1.3, 2.6) 0.409
Hemoglobin (g/dl)
Median (IQR) 11.6(10.4, 13.5) 12.1(10.4, 13.5) 0.277
Adherence (%)*
Median (IQR) 60(0, 100)a 95(20, 100)b 0.001
WHO stage (%)
10 ( 0 ) 1 5 ( 6 . 6 ) 0.001
20 ( 0 ) 1 0 5 ( 4 6 . 3 )
30 ( 0 ) 1 0 7 ( 4 7 . 1 )
4 138(100.0) 0(0)
Weight (kg)
Median (IQR) 57.0(18.8, 65.8) 60.0(53.0, 72.0) 0.001
ART regimen (%)
Non-protease inhibitor-based 119(86.2) 264(91.4) 0.104
Protease inhibitor-based 19(13.8) 25(8.6)
* Missing values
TLC† = Total Lymphocyte Count
a Proportion of patients adherent to ART in the ADC group;12.3%(17/138)
b Proportion of patients adherent to ART in the non-ADC group;65.6%(187/285)AIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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started on efavirence instead of niverapine-based regi-
mens, although in some patients ART was deferred until
the intensive phase was completed. Another reason for the
non-adherence was that the patients were too ill to adhere
to ART medications due to the concurrent co-morbidities
which is a common feature in the sub-Saharan Africa [22].
Our adherence levels to attain immunological recovery
are similar to what other studies have found. In a multi-
centre study in Africa ≥ 95% to ART was necessary to
achieve viral suppression and increase in CD4 counts
[23]. In another study in the USA, adherence of ≥ 95% to
protease inhibitors was necessary to achieve a good
immunological recovery [24]. During ART initiation, the
majority of our patients (89.7%) had been started on non-
protease ART regimens.
A baseline total lymphocyte count ≥ 1200 cells/mm3 was
found to be associated with a short median time to immu-
nological recovery. The hazard of attaining immunologi-
cal recovery increased by 1.8 times when comparing a
patient with a total lymphocyte count of ≥ 1200 cells/
mm3 to one of a lower total lymphocyte count. Some
studies have confirmed the significant association
between a total lymphocyte count of < 1200 cells/mm3
and subsequent poor immunological recovery, disease
progression or mortality [25,26].
In our study, old age was not associated with median time
to immunological recovery, although a significant associ-
ation at bivariate analysis was observed. Later, this associ-
ation between old age and time to immunological
recovery disappeared after adjusting for other variables.
Our findings are similar to those in a cohort of older par-
ticipants in the USA (≥ 55 years) where increasing age was
associated with a slower and lower immunological recov-
ery due to age-related decreases in thymopoiesis [27]. The
2 cohorts differed in their mean age. The mean age of the
patients in our cohort was 40 years whereas for the cohort
in the USA was 55 years.
We also found no effect of sex on median time to immu-
nological recovery. Our findings are similar to other find-
ings else where that show that there are no gender
differences between males and females regarding
response to ART [28]. On the contrary, one study of
antiretroviral-naive patients found that women had a
greater CD4 cell response than men, even after adjusting
for baseline CD4 cell count and viral load. Pharmacoki-
netic differences may have resulted in women having
higher antiretroviral drug levels, which led to more-pro-
found virus suppression and resulted in a greater increase
in CD4 cell count [15].
We recognize our study had the following limitations;
Our study design did not allow for the control of all pos-
sible confounders as it was retrospective cohort. We relied
on measurements taken in the past and where a possible
confounder was not measured we could not control for it.
For example, we were not able to determine the effect of
Body Mass Index (BMI) as height measurements were
only available in about 35 patients. Although the baseline
body weights were available, subsequent measurements
during the follow-up visits were missing and only availa-
ble in 40 patients. A baseline BMI of < 20.3 kg/m2 for men
and < 18.5 kg/m2 for women is predictive of poor immu-
nological recovery, increased morbidity and mortality
[29,30]. We were also not able to determine the effect of
payment for ART services as this information was not also
available, although we found from the chart reviews that
some patients were paying for ART drugs.
The time taken to attain 50 CD4 cells/μl after ART initia-
tion was estimated according nearest date of visit to JCRC
outpatient clinic when the CD4 count was done. This esti-
mation could have over or underestimated the true esti-
mate. To minimize errors in estimation of time to attain
50 CD4 cells/μl both the principal investigator and data
entrant independently calculated the time, and where dif-
ferences arose an average was taken. Overall inter-
observer kappa statistic was 0.68.
Another bias could have resulted from under diagnosis of
ADCs because of lack of diagnostic equipments, a com-
mon finding in resource limited settings. It is surprising
that some of the ADCs were not diagnosed during 2002–
2006 when we reviewed records, whereas had been found
to be prevalent by other study sites. For example in a
nearby main referral hospital, 18% of hospitalized
Kaplan-Meier survival curves comparing time to immunologi- cal recovery among 427 patients during ART initiation at  JCRC during 2002–2006 Figure 2
Kaplan-Meier survival curves comparing time to 
immunological recovery among 427 patients during 
ART initiation at JCRC during 2002–2006.
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patients presented with non-typhoid salmonella, as an
ADC in blood stream [31]. We minimized under diagno-
sis of ADC by chart review to compare diagnosis of what
was in data base whether conforms to what is in the
charts. Another explanation could be that our facility was
predominantly an out-patient setting.
Some of the immune responses after ART initiation were
likely to have been evoked by immune reconstitution syn-
drome (IRS) and diagnosed as ADCs. This is an inflamma-
tory response against infectious and non-infectious
antigens and usually occurs within 12 weeks after ART ini-
tiation [32]. However, only less than 3% of patients had
ADCs within 12 weeks of ART initiation, thus ruling out
the confounding effect of IRS.
We could also not explain a big loss to follow-up of
patients who had enrolled for ART as it was inadequately
documented. Of 609 who were eligible and enrolled for
ART, 182 (29.9%) could not come for second or subse-
quent review visits. We could explain the loss follow-up
could have resulted from deaths due to profound
immuno-suppression at ART initiation. Our findings may
have overestimated individuals achieving immunological
recovery, as those who died from an AIDS-defining dis-
ease shortly after starting ART were excluded from the
analysis. It is also possible that these patients sought treat-
ment in other treatment centers elsewhere. Since 2003,
Uganda has benefited from roll-out program for ART serv-
ices where more centers have been accredited to offer HIV
services and treatment has been either subsided or
Table 3: Bivariate analysis of socio-demographic and clinical characteristics that affect time to immunological recovery among 427 
patients initiated on ART at JCRC, during 2002–2006
Variables Unadjusted
hazard ratio
95% CI p-value
Sex
Male 1.00
Female 1.02 0.81–1.28 0.879
Age (years)
≤ 40 1.00
> 40 1.25 1.01–1.56 0.046
Group status
ADC 1.00
Non-ADC 1.33 1.05–1.69 0.020
CD4 (cells/μl)
>200 1.00
≤ 200 0.77 0.60–0.98 0.034
Viral load (log 10 copies/ml)
< 6.0 1.00
≥ 6.0 0.93 0.88–0.98 0.007
Hemoglobin (g/dl)
≤ 10.0 1.00
> 10.0 0.87 0.64–1.19 0.387
Prophylaxis 1.00
Cotrimoxazole 0.97 0.51–1.83 0.926
Dapsone 0.82 0.58–1.16 0.274
Fluconazole 0.97 0.72–1.30 0.830
None
Adherence level (%)
<95 1.00
≥ 95 2.31 1.84–2.90 0.001
Weight (kg)
≤ 60.0 1.00
> 60.0 0.81 0.64–1.01 0.067
ART regimen
Non-protease inhibitor-based 1.00
Protease inhibitor-based 0.86 0.59–1.26 0.446
Total lymphocyte count (cells/mm3) × 103
< 1.2 1.00
≥ 1.2 1.55 1.04–2.30 0.031AIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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become free. The loss to follow-up of 29.9% could have
resulted into affecting the generalizability of the study
findings. This was minimized by taking precautions to
prevent under or over diagnose ADCs by chart review, and
correct estimation of time to end points from baseline
value by taking independent measurements. Secondly,
the baseline characteristics of the patients who were lost
to follow-up were similar to the patients who had a sub-
sequent follow-up after the baseline visit (CD4 counts
131 vs 115 cells/μl; p = 0.640). Lastly, findings of this
study are strengthened by the relatively homogeneous
study population receiving treatment at a single health
facility using the national treatment protocols. Patients
were all ART-naïve and received a standard triple-drug reg-
imen.
Conclusion
We can draw the following conclusions from the study;
Patients with ADCs take longer to regain their CD4 counts
due to the defect in immune system. This may prolong
their risk to morbidity and mortality as a result of oppor-
tunistic infections. This paper provides a very strong argu-
ment for earlier ART initiation in a Ugandan setting. A key
challenge is how to identify and initiate ART among
patients with less advanced disease. Early Voluntary
Counseling and Testing (VCT), the promotion of VCT
within community settings so that people know their HIV
sero-status and those who are HIV positive are encouraged
so seek early health interventions is one option. Another
option would be starting ART at above the threshold of
200 CD4 cells/μl. Recently, the Ugandan ART guidelines
has recommended initiating ART at 250 and to 350 cells/
μl among pregnant women [3]. The third option would be
active surveillance of among patients interfacing with the
healthcare system. As previously suggested by Lawn SD et
al [4], an obvious target population is those with tubercu-
losis (TB) and HIV-infected pregnant mothers identified
in antenatal clinics (ANCs). These target populations rep-
resent a key opportunity for identifying many patients
with both advanced and less-advanced immunodefi-
ciency. For example, treatment of pregnant mothers at
ANCs is likely not only to result in better outcomes but
also to prevent vertical transmission of HIV. Thus, provi-
sion of facilities for HIV testing and CD4 cell count meas-
urement at antenatal clinics warrants prioritization as
access to ART is increased in low-income countries. Fur-
thermore, although costly, provision of CD4 cell count
Table 4: Multivariate analysis of factors that affect time to immunological recovery among 427 patients initiating ART at JCRC, during 
2002–2006
Variables Adjusted
Hazard ratio
95% CI p-value
Group status
Non-ADC 1.00
ADC 1.31 1.03–1.28 0.028
CD4(cells/μl)
>200 1.00
≤ 200 0.52 0.37–0.77 0.001
Viral load(copies log10/ml)
< 6.0 1.00
≥ 6.0 0.91 0.90–1.04 0.806
Age(years)
≤ 40 1.00
> 40 1.11 0.81–1.67 0.504
Sex
Male 1.00
Female 1.18 0.85–1.67 0.334
Adherence level(%)
< 95 1.00
≥ 95 2.22 1.57–3.15 0.001
Total lymphocyte count (cells/mm3) × 103
<1200 1.00
≥ 1200 1.84 1.22–2.78 0.003AIDS Research and Therapy 2009, 6:17 http://www.aidsrestherapy.com/content/6/1/17
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measurements at voluntary counseling and testing facili-
ties would also help identify other asymptomatic individ-
uals with less-advanced disease who are eligible for ART.
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